<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>ARS Pharmaceuticals announces real-world evidence on neffy effectiveness</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>ARS Pharmaceuticals announces real-world evidence on neffy effectiveness</h1>
  <ul>
<li>Elevate Your Investing Strategy: - Take advantage of TipRanks Premium at 50% off!</li>
<li>Nearly 90% of 545 patients experiencing anaphylaxis symptoms during oral food challenge and allergen immunotherapy were successfully treated with a single dose of neffy by a healthcare provider.</li>
<li>Meta-analyses report a similar proportion of patients, 88.9%, being successfully treated with a single dose of epinephrine intramuscular injection or auto-injector by a healthcare provider for food-induced anaphylaxis.</li>
<li>Try Now&gt;&gt; See Insiders’ Hot Stocks on TipRanks &gt;&gt; Read More on SPRY:</li>
<li>Importantly, these real-world data build upon previously published clinical evidence, including a prospective Phase 3 study assessing the efficacy of neffy for the treatment of oral food challenge-induced anaphylaxis sym</li>
<li>Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news.</li>
<li>In that study, no patients required a second dose of neffy for treatment of the initial anaphylactic reaction.</li>
</ul>
<p><a href="https://finance.yahoo.com/news/ars-pharmaceuticals-announces-real-world-121106007.html">Source</a> · 2025-09-09T12:11:06+00:00</p>
</body>
</html>